Replies to post #10165 on Momenta Pharmaceuticals, Inc. (MNTA)

[joethdo]

Thanks, Dew. I was only half-joking and I think you hit the nail on the head here.

The Obama Administration appears to be favoring the short-term benefit of lower drug prices against the long-term benefit of research and innovation (patent rights etc.). (As you suggest, MNTA perhaps has both benefited and been harmed by this philosophy.)

I am still hopeful that the Supreme Court will see that the contradictions between Classen and Momenta warrant their review.